Sutro Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. on June 10, 2019, covering events occurring on June 7, 2019. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol STRO.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes
- Board Resignation: V. Bryan Lawlis resigned from the Board of Directors, the Audit Committee, and the Nominating and Governance Committee, effective June 12, 2019. The resignation was not the result of any disagreement with the Company.
- Committee Appointment: Joseph Lobacki was appointed to the Audit Committee, effective June 12, 2019, in connection with Dr. Lawlis's resignation.
- Shareholder Vote Results: At the 2019 Annual Meeting, stockholders elected Michael Dybbs, Ph.D., and John G. Freund, M.D., as Class I directors for three-year terms. Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors. The report confirms that the departure of Dr. Lawlis was not due to any disagreement with the Company.
Key Facts for Investor Verification
- Verify the effective date of V. Bryan Lawlis's resignation (June 12, 2019) and the appointment of Joseph Lobacki to the Audit Committee.
- Confirm the voting results for the election of directors Michael Dybbs and John G. Freund, noting the significant number of shares withheld for Mr. Freund.
- Review the ratification vote for Ernst & Young LLP, which received overwhelming support with only 1,497 shares voted against.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.